HRQoL Keratinocyte Carcinomas
Launched by UNIVERSITY HOSPITAL, GHENT · Mar 23, 2021
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
See protocol
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • 1. Patients with one or more premalignant lesion or KC diagnosed by a dermatologist or by histopathology untill 10 years previous to inclusion.
- • Exclusion criteria
- • 1. Patient is younger than 18 years old or unable to provide consent.
- • 2. Patient is unable to remember the diagnosis or symptoms of their KC or premalignant lesion upon request by the doctor.
- • 3. Patient was diagnosed with a melanoma or another NMSC.
- • 4. Patient is unable to understand the task and questionnaires.
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ghent, , Belgium
Rotterdam, , Netherlands
Patients applied
Trial Officials
Lieve Hoorens, MD, PhD
Principal Investigator
Ghent University Hospital, Department of Dermatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials